دورية أكاديمية

A multiplexed assay for quantifying immunomodulatory proteins supports correlative studies in immunotherapy clinical trials.

التفاصيل البيبلوغرافية
العنوان: A multiplexed assay for quantifying immunomodulatory proteins supports correlative studies in immunotherapy clinical trials.
المؤلفون: Whiteaker, Jeffrey R., Zhao, Lei, Schoenherr, Regine M., Huang, Dongqing, Lundeen, Rachel A., Voytovich, Ulianna, Kennedy, Jacob J., Ivey, Richard G., Lin, Chenwei, Murillo, Oscar D., Lorentzen, Travis D., Colantonio, Simona, Caceres, Tessa W., Roberts, Rhonda R., Knotts, Joseph G., Reading, Joshua J., Perry, Candice D., Richardson, Christopher W., Garcia-Buntley, Sandra S., Bocik, William
المصدر: Frontiers in Oncology; 2023, p01-14, 14p
مصطلحات موضوعية: IMMUNE checkpoint inhibitors, CLINICAL trials, DRUG side effects, IMMUNOTHERAPY, MONOCLONAL antibodies
مستخلص: Introduction: Immunotherapy is an effective treatment for a subset of cancer patients, and expanding the benefits of immunotherapy to all cancer patients will require predictive biomarkers of response and immune-related adverse events (irAEs). To support correlative studies in immunotherapy clinical trials, we are developing highly validated assays for quantifying immunomodulatory proteins in human biospecimens. Methods: Here, we developed a panel of novel monoclonal antibodies and incorporated them into a novel, multiplexed, immuno-multiple reaction monitoring mass spectrometry (MRM-MS)-based proteomic assay targeting 49 proteotypic peptides representing 43 immunomodulatory proteins. Results and discussion: The multiplex assay was validated in human tissue and plasma matrices, where the linearity of quantification was >3 orders of magnitude with median interday CVs of 8.7% (tissue) and 10.1% (plasma). Proof-of-principle demonstration of the assay was conducted in plasma samples collected in clinical trials from lymphoma patients receiving an immune checkpoint inhibitor. We provide the assays and novel monoclonal antibodies as a publicly available resource for the biomedical community. [ABSTRACT FROM AUTHOR]
Copyright of Frontiers in Oncology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:2234943X
DOI:10.3389/fonc.2023.1168710